Trials / Active Not Recruiting
Active Not RecruitingNCT04600817
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- TJ Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TJ107 | QW8 |
| DRUG | TJ107 placebo | QW8 |
Timeline
- Start date
- 2020-12-31
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2020-10-23
- Last updated
- 2024-04-15
Locations
16 sites across 2 countries: China, Hong Kong
Source: ClinicalTrials.gov record NCT04600817. Inclusion in this directory is not an endorsement.